EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

European Urology

Volumn 71, Issue 4, 2017, Pages 618-629

  Mottet, Nicolas ^a   Bellmunt, Joaquim ^b,c   Bolla, Michel ^d   Briers, Erik ^e   Cumberbatch, Marcus G ^f   De Santis, Maria ^g   Fossati, Nicola ^h,i   Gross, Tobias ^j   Henry, Ann M ^k   Joniau, Steven ^l   Lam, Thomas B ^m,n   Mason, Malcolm D ^o   Matveev, Vsevolod B ^p   Moldovan, Paul C ^q   van den Bergh, Roderick C N ^r   Van den Broeck, Thomas ^l   van der Poel, Henk G ^s   van der Kwast, Theo H ^t   Rouvière, Olivier ^q   Schoots, Ivo G ^t   Wiegel, Thomas ^u   Cornford, Philip ^v   more..

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e Patients Advocate   (Belgium)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g UNIVERSITY OF WARWICK   (United Kingdom)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j UNIVERSITY OF BERN   (Switzerland)

^k UNIVERSITY OF LEEDS   (United Kingdom)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁿ ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^o CARDIFF UNIVERSITY   (United Kingdom)

^p N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^s NETHERLANDS CANCER INSTITUTE   (Netherlands)

^t ERASMUS MEDICAL CENTER   (Netherlands)

^u UNIVERSITY HOSPITAL ULM   (Germany)

^v ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

Androgen deprivation; Diagnosis; EAU ESTRO SIOG Guidelines; Localised; Prostate cancer; Radiation therapy; Radical prostatectomy; Screening; Staging; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADVANCED CANCER; ARTICLE; BIOCHEMICAL RECURRENCE; BRACHYTHERAPY; BRCA2 GENE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CONFORMAL RADIOTHERAPY; CRYOSURGERY; DIGITAL RECTAL EXAMINATION; DISEASE SURVEILLANCE; EARLY CANCER DIAGNOSIS; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; GENITOURINARY TOXICITY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INCONTINENCE; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; LYMPH NODE DISSECTION; LYMPH NODE IRRADIATION; META ANALYSIS (TOPIC); MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; SURGICAL APPROACH; SYSTEMATIC REVIEW (TOPIC); TOXICITY; TRANSRECTAL ULTRASONOGRAPHY; UROGENITAL TRACT DISEASE; WATCHFUL WAITING; BIOPSY; BLOOD; CANCER GRADING; GENETIC PREDISPOSITION; HYPOFRACTIONATED RADIOTHERAPY; MALE; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSTATE TUMOR; RADIOTHERAPY; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

BIOPSY; BRACHYTHERAPY; CRYOSURGERY; DOSE HYPOFRACTIONATION; EARLY DETECTION OF CANCER; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KALLIKREINS; LYMPH NODE EXCISION; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; NEOPLASM GRADING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 85002820808     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.08.003     Document Type: Article

References (89)

1. [1] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer: Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65 (2014), 124–137.
2. [2] Oxford Centre for Evidence-Based Medicine – levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
3. [3] Arnold, M., Karim-Kos, H.E., Coebergh, J.W., et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 51 (2015), 1164–1187.
4. [4] Leitzmann, M.F., Rohrmann, S., Risk factors for the onset of prostatic cancer: age, location, and behavioural correlates. Clin Epidemiol 4 (2012), 1–11.
5. [5] Esposito, K., Chiodini, P., Capuano, A., et al. Effect of metabolic syndrome and its components on prostate cancer risk: metaanalysis. J Endocrinol Invest 36 (2013), 132–139.
6. [6] Haider, A., Zitzmann, M., Doros, G., Isbarn, H., Hammerer, P., Yassin, A., Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol 193 (2015), 80–86.
7. [7] Albright, F., Stephenson, R.A., Agarwal, N., et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate 75 (2015), 390–398.
8. [8] Hemminki, K., Familial risk and familial survival in prostate cancer. World J Urol 30 (2012), 143–148.
9. [9] Castro, E., Goh, C., Leongamorniert, D., et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 68 (2015), 186–193.
10. [10] Castro, E., Goh, C., Olmos, D., et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31 (2013), 1748–1757.
11. [11] Bancroft, E.K., Page, E.C., Castro, E., et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66 (2014), 489–499.
12. [12] Epstein, J.I., Egevad, L., Amin, M.B., et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40 (2016), 244–252.
13. [13] Hayes, J.H., Barry, M.J., et al. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 311 (2014), 1143–1149.
14. [14] Schröder, F.H., Hugosson, J., Roobol, M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384 (2014), 2027–2035.
15. [15] Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380 (2012), 1778–1786.
16. [16] Banerji, J.S., Wolff, E.M., Massman, J.D. III, Odem-Davis, K., Porter, C.R., Corman, J.M., Prostate needle biopsy outcomes in the era of the U.S. Preventive Services Task Force recommendation against prostate specific antigen based screening. J Urol 195 (2016), 66–73.
17. [17] Arnsrud Godtman, R., Holmberg, E., Lilja, H., Stranne, J., Hugosson, J., Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol 68 (2015), 354–360.
18. [18] Vickers, A.J., Ulmert, D., Sjoberg, D.D., et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ, 346, 2013, f2023.
19. [19] Carlsson, S., Assel, M., Sjoberg, D., et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ, 348, 2014, g2296.
20. [20] Louie, K.S., Seigneurin, A., Cathcart, P., Sasieni, P., Do prostate cancer risk models improve the predictive accuracy of PSA screening?. A meta-analysis. Ann Oncol 26 (2015), 848–864.
21. [21] Droz, J.P., Aapro, M., Balducci, L., et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15 (2014), e404–e414.
22. [22] Eggener, S.E., Large, M.C., Gerber, G.S., et al. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int 112 (2013), 925–929.
23. [23] Loeb, S., Catalona, W.J., The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 6 (2014), 74–77.
24. [24] Bryant, R.J., Sjoberg, D.D., Vickers, A.J., et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst, 107, 2015, djv095.
25. [25] Hara, R., Jo, Y., Fujii, T., et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology 71 (2008), 191–195.
26. [26] Takenaka, A., Hara, R., Ishimura, T., et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis 11 (2008), 134–138.
27. [27] Loeb, S., Vellekoop, A., Ahmed, H.U., et al. Systematic review of complications of prostate biopsy. Eur Urol 64 (2013), 876–892.
28. [28] Futterer, J.J., Briganti, A., De Visschere, P., et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68 (2015), 1045–1053.
29. [29] Le, J.D., Stephenson, S., Brugger, M., et al. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol 192 (2014), 1367–1373.
30. [30] Moore, C.M., Robertson, N.L., Arsanious, N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 63 (2013), 125–140.
31. [31] Siddiqui, M.M., Rais-Bahrami, S., Turkbey, B., et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313 (2015), 390–397.
32. [32] Schoots, I.G., Roobol, M.J., Nieboer, D., Bangma, C.H., Steyerberg, E.W., Hunink, M.G., Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68 (2015), 438–450.
33. [33] Panebianco, V., Barchetti, F., Sciarra, A., et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol, 33, 2015 17.e1–e7.
34. [34] Baco, E., Rud, E., Eri, L.M., et al. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy. Eur Urol 69 (2016), 149–156.
35. [35] Vache, T., Bratan, F., Mège-Lechvallier, F., Roche, S., Rabilloud, M., Rouvière, O., Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology 272 (2014), 446–455.
36. [36] Barentsz, J.O., Weinreb, J.C., Verma, S., et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69 (2016), 41–49.
37. [37] Albertsen, P.C., Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol 25 (2015), 232–237.
38. [38] Wilt, T.J., Brawer, M.K., Jones, K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367 (2012), 203–213.
39. [39] Albertsen, P.C., Moore, D.F., Shih, W., Lin, Y., Lu-Yao, G.L., Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29 (2011), 1335–1341.
40. [40] Thomsen, F.B., Brasso, K., Klotz, L.H., et al. Active surveillance for clinically localized prostate cancer–a systematic review. J Surg Oncol 109 (2014), 830–835.
41. [41] Loeb, S., Bruinsma, S.M., Nicholson, J., et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 67 (2015), 619–626.
42. [42] Montironi, R., Hammond, E.H., Lin, D.W., et al. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch 465 (2014), 623–628.
43. [43] Schoots, I.G., Petrides, N., Giganti, F., et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 67 (2015), 627–636.
44. [44] Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., Loblaw, A., Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28 (2010), 126–131.
45. [45] Steuber, T., Graefen, M., Haese, A., et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 175 (2006), 939–944 discussion 944.
46. [46] de Rooij, M., Hamoen, E.H., Witjes, J.A., Barentsz, J.O., Rovers, M.M., Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70 (2016), 233–245.
47. [47] Vickers, A.J., Savage, C.J., Hruza, M., et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncol 10 (2009), 475–480.
48. [48] Ramsay, C., Pickard, R., Robertson, C., et al. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess 16 (2012), 1–313.
49. [49] Briganti, A., Larcher, A., Abdollah, F., et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61 (2012), 480–487.
50. [50] Briganti, A., Chun, F.K., Salonia, A., et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50 (2006), 1006–1013.
51. [51] Messing, E.M., Manola, J., Yao, J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006), 472–479.
52. [52] Abdollah, F., Karnes, R.J., Suardi, N., et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32 (2014), 3939–3947.
53. [53] Bill-Axelson, A., Holmberg, L., Garmo, H., et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370 (2014), 932–942.
54. [54] Schreiber, D., Wong, A.T., Rineer, J., et al. Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study. J Clin Pathol 68 (2015), 453–457.
55. [55] Yossepowitch, O., Eggener, S.E., Serio, A.M., et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008), 950–959.
56. [56] Walz, J., Joniau, S., Chun, F.K., et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 107 (2011), 765–770.
57. [57] Spahn, M., Joniau, S., Gontero, P., et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58 (2010), 1–7 discussion 10-1.
58. [58] Joniau, S., Briganti, A., Gontero, P., et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 67 (2015), 157–164.
59. [59] Ficarra, V., Novara, G., Rosen, R.C., et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62 (2012), 405–417.
60. [60] Haglind, E., Carlsson, S., Stranne, J., et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial. Eur Urol 68 (2015), 216–225.
61. [61] Zelefsky, M.J., Levin, E.J., Hunt, M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 1124–1129.
62. [62] Kuban, D.A., Levy, L.B., Cheung, M.R., et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 79 (2011), 1310–1317.
63. [63] Zietman, A.L., Bae, K., Slater, J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 28 (2010), 1106–1111.
64. [64] Beckendorf, V., Guerif, S., Le Prisé, E., et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80 (2011), 1056–1063.
65. [65] Heemsbergen, W.D., Al-Mamgani, A., Slot, T., Dielwart, M.F., Lebesque, J.V., Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110 (2014), 104–109.
66. [66] Kalbasi, A., Li, J., Berman, A., et al. Dose-escalated irradiation and overall survival in men with non-metastatic prostate cancer. JAMA Oncol 1 (2015), 897–906.
67. [67] Dearnaley, D., Syndikus, I., Mossop, H., et al. CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17 (2016), 1047–1060.
68. [68] Lee, W.R., Dignam, J.J., Amin, M.B., et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 34 (2016), 2325–2332.
69. [69] Incrocci, L., Wortel, R.C., Alemayehu, W.G., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17 (2016), 1061–1069.
70. [70] Jones, C.U., Hunt, D., McGowan, D.G., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365 (2011), 107–118.
71. [71] Bolla, M., Van Tienhoven, G., Warde, P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11 (2010), 1066–1073.
72. [72] Bolla, M., de Reijke, T.M., Van Tienhoven, G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360 (2009), 2516–2527.
73. [73] Pilepich, M.V., Winter, K., Lawton, C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005), 1285–1290.
74. [74] Mason, M.D., Parulekar, W.R., Sydes, M.R., et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 33 (2015), 2143–2150.
75. [75] Fizazi, K., Faivre, L., Lesaunier, F., et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 16 (2015), 787–794.
76. [76] Lawton, C.A., DeSilvio, M., Roach, M. III, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007), 646–655.
77. [77] James, N., Spears, M.R., Clarke, N.W., et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol 2 (2016), 348–357.
78. [78] Bolla, M., van Poppel, H., Tombal, B., et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380 (2012), 2018–2027.
79. [79] Wiegel, T., Bartkowiak, D., Bottke, D., et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66 (2014), 243–250.
80. [80] Thompson, I.M., Tangen, C.M., Paradelo, J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181 (2009), 956–962.
81. [81] Fossati, N., Karnes, R.J., Cozzarini, C., et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69 (2016), 728–733.
82. [82] Wallis, C.J., Mahar, A.L., Choo, R., et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ, 352, 2016, i851.
83. [83] Ash, D., Flynn, A., Battermann, J., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57 (2000), 315–321.
84. [84] Grimm, P., Billiet, I., Bostwick, D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109:Suppl 1 (2012), 22–29.
85. [85] Budäus, L., Bolla, M., Bossi, A., et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 61 (2012), 112–127.
86. [86] Martens, C., Pond, G., Webster, D., et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 5 (2006), 9–13.
87. [87] Vordermark, D., Wulf, J., Markert, K., et al. 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey. Acta Oncol 45 (2006), 708–716.
88. [88] Hoskin, P.J., Columbo, A., Henry, A., et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 107 (2013), 325–332.
89. [89] Ramsay, C.R., Adewuyi, T.E., Gray, J., et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess 19 (2015), 1–490.